http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html <p>ATLANTA, July 16, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.</p> <p align="justify"><strong>Conference Call Details</strong></p> <p>To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html Thu, 16 Jul 2026 07:00:00 -0400 FA FA http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html <p>ATLANTA, July 16, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.</p> <p align="justify"><strong>Conference Call Details</strong></p> <p>To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or http://www.streetinsider.com/Press+Releases/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html Thu, 16 Jul 2026 07:00:00 -0400 FA FA http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html <p>ATLANTA, July 16, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.</p> <p align="justify"><strong>Conference Call Details</strong></p> <p>To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html Thu, 16 Jul 2026 07:00:00 -0400 FA FA http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html <p>ATLANTA, July 16, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation (NASDAQ: FA), a global software and data company, will issue its second quarter 2026 financial results on Thursday, August 6, 2026 prior to the Company’s earnings conference call, which will be held at 8:30 a.m. ET on the same day.</p> <p align="justify"><strong>Conference Call Details</strong></p> <p>To participate in the conference call, please dial 800-274-8461 (domestic) or 203-518-9814 (international) approximately ten minutes before the 8:30 a.m. ET start. Please mention to the operator that you are dialing in for the First Advantage second quarter 2026 earnings call or http://www.streetinsider.com/Globe+Newswire/First+Advantage+to+Release+Second+Quarter+2026+Financial+Results+and+Hold+Investor+Conference+Call+on+August+6%2C+2026/26776405.html Thu, 16 Jul 2026 07:00:00 -0400 FA FA http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Press+Releases/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html <p align="left"><em>Issued on behalf of Conexeu Sciences Inc.</em></p> <p align="left"><em>As GLP-1 medications transform millions of bodies, a new multi-billion-dollar aesthetics opportunity is opening beneath the surface, and Conexeu Sciences Inc. (Nasdaq: CNXU) is aiming its investigational CXU™ platform squarely at it</em></p> <p align="left">RENO, Nevada, July 15, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=epNTIMqM8OhM8M025TIsDmHqYx2iOQ0zFIu0iXvqqNDTWmAwRa_OTsIgJgSK7s8LUqpuaMclSCs6_VJwb1ft3f8ydl1JpZ2ybRCiuetkRoc=" rel="nofollow" target="_blank">Energy Metal News</a> News Commentary — The most disruptive force in medicine right now is not a device or a diagnosis. It is a class of drugs. GLP-1 medications like Ozempic® and Wegovy® have moved from diabetes management into http://www.streetinsider.com/Globe+Newswire/A+Weight-Loss+Revolution+Is+Reshaping+Bodies.+This+Preclinical+Biotech+Wants+to+Build+What+Comes+Next/26771572.html Wed, 15 Jul 2026 08:45:00 -0400 ANAB CNXU CNXU CNXU CVE FA MPC http://www.streetinsider.com/Options/First+Advantage+%28FA%29+6K+contracts+of+July+22.50+calls+trade/26762013.html <p>First Advantage (NASDAQ: FA) 30-day option implied volatility is at 66; compared to its 52-week range of 32 to 126 with a focus on 6K contracts of July 22.50 calls.</p> http://www.streetinsider.com/Options/First+Advantage+%28FA%29+6K+contracts+of+July+22.50+calls+trade/26762013.html Mon, 13 Jul 2026 14:15:20 -0400 FA http://www.streetinsider.com/Analyst+PT+Change/First+Advantage+%28FA%29+PT+Raised+to+%2424+at+BMO+Capital/26750159.html BMO Capital analyst Jeffrey Silber raised the price target on First Advantage (NASDAQ: FA) to $24.00 (from $19.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/First+Advantage+%28FA%29+PT+Raised+to+%2424+at+BMO+Capital/26750159.html Thu, 09 Jul 2026 07:37:41 -0400 FA http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:FA" idsrc="xmltag.org" >First Advantage Corporation</span> (<span>NASD</span>: FA) will replace <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings Inc.</span> (NYSE: KW) in the S&amp;P SmallCap 600 effective prior to the opening of trading on <chron>Tuesday, June 16</chron>. A consortium led by KW's CEO with <span value="Toronto:FFH" idsrc="xmltag.org" >Fairfax Financial Holdings Limited</span> (TSE: FFH) is acquiring <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings</span> in a deal expected to close soon, pending final closing conditions.</p> <p>Following is a summary of the changes that will take place prior to the open of trading on the effective http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html Thu, 11 Jun 2026 18:41:00 -0400 FA FFH FFH KW O.00171164 O.03712323 O.13013684 O.50996177 SPGI http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:FA" idsrc="xmltag.org" >First Advantage Corporation</span> (<span>NASD</span>: FA) will replace <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings Inc.</span> (NYSE: KW) in the S&amp;P SmallCap 600 effective prior to the opening of trading on <chron>Tuesday, June 16</chron>. A consortium led by KW's CEO with <span value="Toronto:FFH" idsrc="xmltag.org" >Fairfax Financial Holdings Limited</span> (TSE: FFH) is acquiring <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings</span> in a deal expected to close soon, pending final closing conditions.</p> <p>Following is a summary of the changes that will take place prior to the open of trading on the effective http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html Thu, 11 Jun 2026 18:41:00 -0400 FA FFH FFH KW O.00171164 O.03712323 O.13013684 O.50996177 SPGI http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:FA" idsrc="xmltag.org" >First Advantage Corporation</span> (<span>NASD</span>: FA) will replace <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings Inc.</span> (NYSE: KW) in the S&amp;P SmallCap 600 effective prior to the opening of trading on <chron>Tuesday, June 16</chron>. A consortium led by KW's CEO with <span value="Toronto:FFH" idsrc="xmltag.org" >Fairfax Financial Holdings Limited</span> (TSE: FFH) is acquiring <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings</span> in a deal expected to close soon, pending final closing conditions.</p> <p>Following is a summary of the changes that will take place prior to the open of trading on the effective http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html Thu, 11 Jun 2026 18:41:00 -0400 FA FFH FFH KW O.00171164 O.03712323 O.13013684 O.50996177 SPGI http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:FA" idsrc="xmltag.org" >First Advantage Corporation</span> (<span>NASD</span>: FA) will replace <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings Inc.</span> (NYSE: KW) in the S&amp;P SmallCap 600 effective prior to the opening of trading on <chron>Tuesday, June 16</chron>. A consortium led by KW's CEO with <span value="Toronto:FFH" idsrc="xmltag.org" >Fairfax Financial Holdings Limited</span> (TSE: FFH) is acquiring <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings</span> in a deal expected to close soon, pending final closing conditions.</p> <p>Following is a summary of the changes that will take place prior to the open of trading on the effective http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html Thu, 11 Jun 2026 18:41:00 -0400 FA FFH FFH KW O.00171164 O.03712323 O.13013684 O.50996177 SPGI http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:FA" idsrc="xmltag.org" >First Advantage Corporation</span> (<span>NASD</span>: FA) will replace <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings Inc.</span> (NYSE: KW) in the S&amp;P SmallCap 600 effective prior to the opening of trading on <chron>Tuesday, June 16</chron>. A consortium led by KW's CEO with <span value="Toronto:FFH" idsrc="xmltag.org" >Fairfax Financial Holdings Limited</span> (TSE: FFH) is acquiring <span value="NYSE:KW" idsrc="xmltag.org" >Kennedy-Wilson Holdings</span> in a deal expected to close soon, pending final closing conditions.</p> <p>Following is a summary of the changes that will take place prior to the open of trading on the effective http://www.streetinsider.com/Press+Releases/First+Advantage+Set+to+Join+S%26amp%3BP+SmallCap+600/26637102.html Thu, 11 Jun 2026 18:41:00 -0400 FA FFH FFH KW O.00171164 O.03712323 O.13013684 O.50996177 SPGI